Contrast-Enhanced Ultrasound vs Conventional US-guided Percutaneous Needle Biopsy for Pancreatic Diseases: Prospective Multicenter Randomized Controlled Trial

Inclusion Criteria: * Age ≥18 years, WHO/ECOG scores \<2; * Radiographic examination reveal focal pancreatic lesions; * No history of local treatment for pancreatic lesions, systemic chemotherapy, targeting, immunotherapy, etc; * Normal organ function, including the following criteria: 1. Routine blood test: Hb≥80 g/L; PLT≥50×109/L; 2. Coagulation function test: PT\<20s. Exclusion Criteria: * The lesions could not be shown by ultrasound and contrast-enhanced ultrasound; * Allergic to ultrasound contrast agent; * Cardiovascular and cerebrovascular diseases, liver, kidney and lung failure with significant clinical symptoms; * History of unexplained bleeding, severe anemia, bleeding tendency or uncorrected coagulopathy; * Combined with active infection; * Massive ascites; * Patients or family members do not agree to enter the study; * Pregnant or lactating women; * The investigator considers that there are any other factors that may be inappropriate for inclusion or affect the subject's participation in the study.